Table 1 Background characteristics of patients
From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
Patients | 40 |
|---|---|
Age, median [range] | 67 [33–78] |
Sex, male (%) | 15 (37.5) |
BW (kg), median [range] | 58.0 [35.3–97.1] |
Histopathology, follicular (%) | 15 (37.5) |
Performance status, ≥ 1 | 17 (42.5) |
Sum of tumor diameters (mm), median [range] | 82 [11–169] |
Tumor related symptoms at baseline, yes (%) | 24 (60) |
Thyroglobulin doubling time, year | 0.7 (0.12–3.0) |
Treatment period (months), median [range] | 29.5 [6.8–61.5] |
Observation period (months), median [range] | 32.5 [7.4–61.5] |
Dose Intensity, median [range] | 9.6 [4.0–16.4] |
Best response in RECIST criteria, PR (%) | 29 (72.5) |
eGFR at baseline (mL/min/1.73 m2), median [range] | 72.2 (43.6–119.1) |
Proteinuria grade 1 at baseline, yes (%) | 2 (5) |
Past hypertension history (%) | 24 (60) |
Past diabetes mellitus history (%) | 3 (7.5) |
Past renal history (%) | 6 (15) |
Renal metastasis, baseline (%) | 3 (7.5) |
latest (%) | 3 (7.5) |
Liver metastasis, baseline (%) | 5 (12.5) |
latest (%) | 7 (17.5) |
Proteinuria grade 3, yes (%) | 21 (52.5) |
Treatment continuation, yes (%) | 20 (50) |
Treatment termination due to renal problem, yes (%) | 7 (17.5) |